An open label, randomized study looking at the efficacy and safety ofoneSingle Tablet Regimen of Emtricitabine/Rilpivirine/TenofovirDisoproxil Fumarate compared with another Single Tablet Regimen ofEfavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV infectedpeople who have not been or are not being treated for HIV.

Phase 1

Conditions: Human Immunodeficiency Virus (Type 1) Infection
MedDRA version: 14.0Level: LLTClassification code 10020192Term: HIV-1System Organ Class: 10021881 - Infections and infestations
Therapeutic area: Diseases [C] - Immune System Diseases [C20]

Registration Number: EUCTR2010-024007-27-BE

Lead Sponsor: Gilead Sciences, Inc.

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: ot Recruiting

Sex: All

Target Recruitment: 700

Inclusion Criteria

•The ability to understand and sign a written informed consent form,
which must be obtained prior to initiation of study procedures.
•Plasma HIV 1 RNA levels = 2,500 copies/mL at screening
•No prior use of any approved or experimental anti-HIV drug for any
length of time.
•Screening genotype report showing sensitivity to EFV, FTC, TDF, and
lack of the RPV mutations K101E/P, E138A/G/K/Q/R, Y181C/I/V, and
H221Y
•Normal ECG (or if abnormal, determined by the Investigator to be not
clinically significant)
•Hepatic transaminases (AST and ALT) = 5 x upper limit of normal (ULN)
•Total bilirubin = 1.5 mg/dL
•Adequate hematologic function (absolute neutrophil count = 750/mm3;
platelets = 50,000/mm3; hemoglobin = 8.5 g/dL)
•Serum amylase = 5 x ULN (subjects with serum amylase > 5 x ULN will
remain eligible if serum lipase is = 5 x ULN)
•Adequate renal function:
Estimated glomerular filtration rate = 50 mL/min according to the
Cockcroft Gault formula:
Male: ((140 – age in years) x (wt in kg))/ (72 x (serum creatinine in
mg/dL)) = CLcr (mL/min)
Female: ((140 – age in years) x (wt in kg) x 0.85) / (72 x (serum
creatinine in mg/dL) = CLcr (mL/min)
•Females of childbearing potential (as defined in Section 7.8.1) must
agree to utilize protocol-recommended methods of contraception (as
defined in Section 7.8.1), or be non-heterosexually active, practice
sexual abstinence or have a vasectomized partner) from screening
throughout the duration of study period and for 12 weeks following the
last dose of study drug.
Female subjects who utilize hormonal contraceptive as one of their birth
control methods must have used the same method for at least three
months prior to study dosing
Female subjects who have stopped menstruating for < 12 months, or
serum follicle stimulating hormone level is not within the postmenopausal
range must agree to utilize protocol recommended methods
of contraception.
•Male subjects must agree to utilize protocol-recommended methods of
contraception (as defined in Section 7.8.2) during heterosexual
intercourse from the screening visit, throughout the duration of the
study and for 12 weeks following discontinuation of investigational
medicinal product, or be non-heterosexually active or practice sexual
abstinence.
•Adult (= 18 years) males or non-pregnant females
Are the trial subjects under 18? no
Number of subjects for this age range: 0
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 670
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 30

Exclusion Criteria

Subjects who meet any of the following exclusion criteria are not to be
enrolled in (or may be discontinued from) this study:
•A new AIDS defining condition diagnosed within the 30 days prior to
screening (refer to Appendix 5)
•Females who are breastfeeding
•Positive serum pregnancy test (female of childbearing potential)
•Proven acute hepatitis in the 30 days prior to study entry.
•Subjects receiving drug treatment for Hepatitis C, or subjects who are
anticipated to receive treatment for Hepatitis C during the course of the
study.
•Have a history of ongoing active liver disease or experiencing
decompensated cirrhosis (e.g., ascites, encephalopathy, etc.)
•Have an implanted defibrillator or pacemaker
•Current alcohol or substance use judged by the Investigator to
potentially interfere with subject study compliance.
•A history of malignancy within the past 5 years (prior to screening) or
ongoing malignancy other than cutaneous Kaposi's sarcoma (KS), basal
cell carcinoma, or resected, non-invasive cutaneous squamous
carcinoma. Subjects with cutaneous KS are eligible, but must not have
received any systemic therapy for KS within 30 days of Baseline and
must not be anticipated to require systemic therapy during the study.
•Active, serious infections (other than HIV 1 infection) requiring
parenteral antibiotic or antifungal therapy within 30 days prior to
Baseline (e.g. requiring inpatient treatment or prolonged outpatient
intravenous infusion therapy, exception: intramuscular penicillin for
treatment of syphilis).
•Subjects receiving ongoing therapy or anticipated to need to initiate
drugs or herbal/natural supplements during the study that are
contraindicated or not recommended for use as indicated in the table
below, including drugs not to be used with FTC, EFV, RPV, TDF, and
Atripla (refer to the individual agent's Prescribing Information); or
subjects with known allergies to the excipients of the FTC/RPV/TDF
single tablet regimen and/or Atripla tablets.
Drug Class Agents Disallowed*
Analeptics: Modafinil
Antiarrhythmics: Bepridil
Anticonvulsants: Phenobarbital, carbamazepine, oxcarbazepine, and
phenytoin
Antibiotics: Rifabutin, rifampin, rifapentine, telithromycin,
troleandomycin
Antibacterials: Telithromycin
Antidiabetics: Pioglitazone, troglitazone
Antifungals: Voriconazole
Antihistamines: Astemizole, Terfenadine
Antimycobacterials: Rifampin, Rifapentine, Rifabutin
Calcium Channel Blockers: Bepridil
GI Motility Agents: Cisapride
Glucocorticoids (systemic): Dexamethasone
Ergot Derivatives: Ergotamine, Ergonovine, Dihydroergotamine,
Methylergonovine
Herbal/Natural Supplements: St. John's Wort, Echinaccea
Progestogens: Megestrol Acetate
Proton Pump Inhibitors: Omeprazole, lansoprazole, rabeprazole,
pantoprazole, esomeprazole
Neuroleptics: Pimozide
Sedatives/Hypnotics: Midazolam, Triazolam
* Administration of any of the above medications must be discontinued
at least 21 days prior to the Baseline/Day 1 visit and for the duration of
the study.
•Participation in any other clinical trial without prior approval from the
sponsor is prohibited while participating in this trial.
•Have been treated with immunosuppressant therapies or
chemotherapeutic agents within 3 months of study screening, or
expected to receive these agents or systemic steroids for
immunosuppression during the study (e.g., corticosteroids,
immunoglobulins, and other immune- or cytokine based therapies).
•Any o